A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.
Year: 2012
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: Dana-Farber Cancer Institute, Stanford Medicine, Stanford University, The University of Texas MD Anderson Cancer Center, Willamette Valley Cancer Institute and Research Center, Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, Columbia University Irving Medical Center, Columbia University, University of Washington Medical Center, City Of Hope National Medical Center, Seagen (United States), Washington University in St. Louis
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2583468445